BiotechTube

enzalutamide + Androgen Deprivation

Phase 2Completed
1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Prostate Cancer

Conditions

Prostate Cancer

Trial Timeline

Apr 1, 2014 → Jun 5, 2019

NCT ID
NCT02057939

About enzalutamide + Androgen Deprivation

enzalutamide + Androgen Deprivation is a phase 2 stage product being developed by Astellas Pharma for Prostate Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT02057939. Target conditions include Prostate Cancer.

What happened to similar drugs?

20 of 20 similar drugs in Prostate Cancer were approved

Approved (20) Terminated (4) Active (0)
✅EnzalutamideAstellas PharmaApproved
✅EnzalutamideAstellas PharmaApproved
✅Enzalutamide + Androgen deprivation therapy (ADT)Astellas PharmaApproved
✅Enzalutamide + Abiraterone + Placebo for Enzalutamide + PrednisoneAstellas PharmaApproved
✅EnzalutamideAstellas PharmaApproved
✅Enzalutamide + FlutamideAstellas PharmaApproved
✅LeuprolideAstellas PharmaApproved

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02057939Phase 2Completed

Competing Products

20 competing products in Prostate Cancer

See all competitors
ProductCompanyStageHype Score
NBTXR3 activated by IMRT only + NBTXR3 activated by Brachytherapy & IMRTNanobiotixPhase 1/2
18
PemetrexedEli LillyPhase 2
35
5 mg Tadalafil + Placebo + 0.2 mg TamsulosinEli LillyPhase 3
40
SRF617 + etrumadenant + zimberelimabCoherus BioSciencesPhase 2
17
Abemaciclib + Placebo + Abiraterone acetate + PrednisoneEli LillyPhase 2/3
42
eFT508eFFECTOR TherapeuticsPhase 2
17
EnhertuDaiichi SankyoPhase 2
42
Ifinatamab deruxtecan + Docetaxel + Prednisone + Rescue MedicationDaiichi SankyoPhase 3
47
exatecan mesylateDaiichi SankyoPhase 2
35
PLX3397Daiichi SankyoPhase 2
27
Valemetostat + DarolutamideDaiichi SankyoPhase 1
36
Enzalutamide + Placebo + Androgen deprivation therapy (ADT)Astellas PharmaPhase 3
44
EnzalutamideAstellas PharmaPhase 2
35
Enzalutamide + Docetaxel + Prednisolone + PlaceboAstellas PharmaPhase 3
40
EnzalutamideAstellas PharmaPhase 2
35
Enzalutamide + Metformin HydrochlorideAstellas PharmaPhase 1
29
degarelix + GoserelinAstellas PharmaPhase 3
40
Enzalutamide, 160mg, 40 mg soft capsules, once dailyAstellas PharmaPre-clinical
26
enzalutamide + abiraterone acetate + prednisoneAstellas PharmaPhase 2
35
enzalutamide + abiraterone acetate + prednisone + Leuprolide acetateAstellas PharmaPhase 2
42